Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest
Clinical trials sponsored by Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest, explained in plain language.
-
New combo shows promise in stomach cancer battle
Disease control OngoingThis study tests whether a combination of ramucirumab plus FOLFIRI can help people with advanced stomach or gastroesophageal junction cancer live longer compared to the current standard of ramucirumab plus paclitaxel. The trial includes 429 adults whose cancer progressed after on…
Phase: PHASE2, PHASE3 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 29, 2026 03:57 UTC
-
Experimental immune therapy combo targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests an experimental drug called IMP321, which aims to boost the immune system's ability to fight cancer. It is given alongside standard treatments like chemotherapy or immunotherapy to people with advanced solid tumors that have spread. The main goal is t…
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 29, 2026 03:57 UTC
-
New triple therapy shows promise for rare, Hard-to-Treat biliary cancers
Disease control OngoingThis study tests a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive bile duct or gallbladder cancer that cannot be removed by surgery. The goal is to see if this triple t…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC